Dorsey & Whitney Trust CO LLC Has $486,000 Stake in Thermo Fisher Scientific (TMO)

Dorsey & Whitney Trust CO LLC trimmed its stake in Thermo Fisher Scientific (NYSE:TMO) by 14.3% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,354 shares of the medical research company’s stock after selling 394 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Thermo Fisher Scientific were worth $486,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Atria Investments LLC increased its stake in Thermo Fisher Scientific by 4.6% in the fourth quarter. Atria Investments LLC now owns 8,254 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 364 shares during the last quarter. Bank of Montreal Can increased its stake in Thermo Fisher Scientific by 16.3% in the fourth quarter. Bank of Montreal Can now owns 290,892 shares of the medical research company’s stock valued at $55,235,000 after purchasing an additional 40,877 shares during the last quarter. Creative Planning increased its stake in Thermo Fisher Scientific by 12.7% in the fourth quarter. Creative Planning now owns 23,020 shares of the medical research company’s stock valued at $4,371,000 after purchasing an additional 2,592 shares during the last quarter. First National Trust Co increased its stake in Thermo Fisher Scientific by 33.9% in the fourth quarter. First National Trust Co now owns 4,897 shares of the medical research company’s stock valued at $930,000 after purchasing an additional 1,239 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. increased its stake in Thermo Fisher Scientific by 6.1% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 4,483 shares of the medical research company’s stock valued at $851,000 after purchasing an additional 257 shares during the last quarter. 86.52% of the stock is owned by institutional investors.

Get Thermo Fisher Scientific alerts:

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 40,000 shares of the company’s stock in a transaction dated Thursday, March 22nd. The stock was sold at an average price of $210.16, for a total transaction of $8,406,400.00. Following the completion of the sale, the chief executive officer now directly owns 334,622 shares in the company, valued at $70,324,159.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction dated Monday, March 5th. The stock was sold at an average price of $204.60, for a total value of $511,500.00. The disclosure for this sale can be found here. Insiders have sold 43,500 shares of company stock valued at $9,129,330 over the last 90 days. 0.49% of the stock is currently owned by insiders.

Shares of NYSE:TMO opened at $214.94 on Friday. The stock has a market cap of $84.76 billion, a price-to-earnings ratio of 22.65, a PEG ratio of 1.54 and a beta of 1.14. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. Thermo Fisher Scientific has a 12 month low of $170.07 and a 12 month high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 25th. The medical research company reported $2.50 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.42 by $0.08. The company had revenue of $5.85 billion during the quarter, compared to analyst estimates of $5.62 billion. Thermo Fisher Scientific had a return on equity of 16.09% and a net margin of 10.24%. The firm’s revenue was up 22.8% on a year-over-year basis. During the same period in the prior year, the firm posted $2.08 earnings per share. research analysts predict that Thermo Fisher Scientific will post 10.91 EPS for the current fiscal year.

TMO has been the subject of several analyst reports. ValuEngine upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded Thermo Fisher Scientific from a “sell” rating to a “hold” rating in a research note on Saturday, January 20th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $223.00 to $227.00 and gave the company an “overweight” rating in a research note on Thursday, February 1st. Leerink Swann reiterated an “outperform” rating and issued a $239.00 target price (up from $200.00) on shares of Thermo Fisher Scientific in a research note on Thursday, February 1st. They noted that the move was a valuation call. Finally, Bank of America upped their target price on Thermo Fisher Scientific from $235.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, February 1st. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $224.38.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)